Figure 5.

Chronic CL-316243 treatment reduces the hyperinsulinemia and metastases burden in MKR^+/+ mice. The authors treated 8- to 10-week-old MKR^+/+ and control mice with CL-316243 or vehicle for three weeks (6 to 8 mice per group). (A) Whole body fat (% of total body weight) was measured after 10 days of treatment. (B) Blood glucose was measured after seven days of treatment. (C) Body weight was measured weekly. (D) Serum insulin was measured after 21 days of treatment. Data are expressed as SEM. *, P ≤ 0.05 and for control vs. MKR. ^#, P ≤ 0.05 for CL-316243 vs. vehicle. (E) Mvt1 cells (10,000) were injected intravenously into 8- to 10-week-old control and MKR^+/+ mice (7 to 9 per group). Mice were then treated with CL-316243 or vehicle for three weeks. Mice were sacrificed and the numbers of lung macrometasatases were counted. Data are expressed as SEM. *, P ≤ 0.05 for control vs. MKR^+/+. ^#, P ≤ 0.05 for CL-316243 vs. vehicle.